Table 1.
Description of sample
| Group | MS patients | OASIS-3 dataset | Test statistics |
|---|---|---|---|
| Number of Participants | 70 | 273 | - |
| Number of Sessions | 234 | 700 | - |
| Age in years (mean ± SD) | 35.2 ± 8.1 | 65.9 ± 8.8 | t(69) = 72.68, p < 0.001 |
| Sex (m/f) | 49 f/21 m | 159 f/114 m | χ2(1) = 3.22, p = 0.07 |
| Time since first symptoms in months at first presentation (mean ± SD, n) | 3.5 ± 0.9, 70 | - | - |
| Patients with immunotherapy | 35 | - | - |
| Patients with relapse during examination period | 34 | - | - |
| EDSS (median, range, number of complete sessions, number of incomplete sessions) | 1.5, [0–3.5], 227, 7 | - | - |
| BRB-N PASAT3 (mean ± SD, number of complete sessions, number of incomplete sessions) | 51.9 ± 6.7, 210, 24 | - | - |
| BRB-N SDMT (mean ± SD, number of complete sessions, number of incomplete sessions) | 64.2 ± 12.8, 210, 24 | - | - |
| BDI-II (mean ± SD, number of complete sessions, number of incomplete sessions) | 6 ± 7.7, 145, 89 | - | - |
| MMSE (mean ± SD, number of complete subjects, number of incomplete subjects) | - | 28.89 ± 1.64, 267, 6 | - |
Medication in MS patients: interferon beta-1a (n = 10), interferon-beta-1b (5), dimethyl fumarate (9), glatiramer acetate (9), teriflunomide (2)#. MS: multiple sclerosis; mean: arithmetic mean; SD: standard deviation; n: number of sessions